New Zealand markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.13-0.19 (-0.70%)
At close: 04:00PM EDT
26.27 -0.86 (-3.17%)
After hours: 05:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close27.32
Open27.22
Bid27.10 x 200
Ask27.13 x 100
Day's range27.00 - 27.55
52-week range16.26 - 32.00
Volume1,071,582
Avg. volume1,648,914
Market cap4.029B
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-5.34
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est43.67
  • PR Newswire

    Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego. Presentations will include late-breaking microbiologic data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) in patien

  • PR Newswire

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

  • PR Newswire

    Insmed To Present at Three March Conferences

    Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: